Related Experiment Video

Updated: Jul 5, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

CTLA-4: negative regulator of the immune response and a target for cancer therapy

Ulrich Keilholz1

  • 1Department of Medicine III, Charity, Campus Benjamin Franklin, Berlin, Germany. ulrich.keilholz@charite.de

Journal of Immunotherapy (Hagerstown, Md. : 1997)
|May 9, 2008
PubMed

Insights

Blocking Cytotoxic T-lymphocyte antigen-4 (CTLA-4) with antibodies enhances T-cell immunity against tumors. This approach shows promise for treating metastatic melanoma and other cancers, with ongoing clinical trials evaluating its efficacy and safety.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • T-cell-mediated immunity is crucial for cancer immunotherapy.
  • Cytotoxic T-lymphocyte antigen-4 (CTLA-4) acts as a key inhibitor of T-cell activation.
  • Blocking CTLA-4 can potentially enhance anti-tumor immune responses.

Purpose of the Study:

  • To review existing data on anti-CTLA-4 monoclonal antibodies (mAbs) in cancer treatment.
  • To discuss clinical considerations from early trials of CTLA-4 blockade therapy.
  • To provide an overview of current and planned clinical trials for anti-CTLA-4 mAb therapy.

Main Methods:

  • Review of published studies and clinical trial data involving anti-CTLA-4 mAbs.
  • Analysis of efficacy and tolerability data in patients with metastatic melanoma and other cancers.
  • Synthesis of information on clinical considerations and future trial designs.

Main Results:

  • Preliminary data indicate good efficacy and tolerability of anti-CTLA-4 mAbs in certain cancers.
  • CTLA-4 blockade potentiates T-cell responses against tumors.
  • Early clinical trials are yielding valuable insights into this therapeutic strategy.

Conclusions:

  • Anti-CTLA-4 mAb therapy represents a novel and promising approach to cancer immunotherapy.
  • Further clinical trials are essential to fully establish the role of CTLA-4 blockade in treating various cancers.
  • Understanding clinical considerations is key to optimizing the use of these agents.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...